Suppr超能文献

相似文献

1
Aldosterone: role in the cardiometabolic syndrome and resistant hypertension.
Prog Cardiovasc Dis. 2010 Mar-Apr;52(5):401-9. doi: 10.1016/j.pcad.2009.12.004.
2
Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension.
Ann Intern Med. 2009 Jun 2;150(11):776-83. doi: 10.7326/0003-4819-150-11-200906020-00005.
4
Mineralocorticoid receptors in the pathogenesis of insulin resistance and related disorders: from basic studies to clinical disease.
Am J Physiol Regul Integr Comp Physiol. 2021 Mar 1;320(3):R276-R286. doi: 10.1152/ajpregu.00280.2020. Epub 2021 Jan 13.
5
Mineralocorticoid receptor antagonists and the metabolic syndrome.
Curr Hypertens Rep. 2010 Aug;12(4):252-7. doi: 10.1007/s11906-010-0126-2.
6
Role of mineralocorticoid receptor in insulin resistance.
Curr Opin Endocrinol Diabetes Obes. 2012 Jun;19(3):168-75. doi: 10.1097/MED.0b013e3283533955.
7
Mineralocorticoid antagonism and cardiac hypertrophy.
Curr Hypertens Rep. 2008 Jun;10(3):216-21. doi: 10.1007/s11906-008-0041-y.
8
Vascular Consequences of Aldosterone Excess and Mineralocorticoid Receptor Antagonism.
Curr Hypertens Rev. 2017;13(1):46-56. doi: 10.2174/1573402113666170228151402.
10
The Role of Aldosterone in Obesity-Related Hypertension.
Am J Hypertens. 2016 Apr;29(4):415-23. doi: 10.1093/ajh/hpw003. Epub 2016 Feb 28.

引用本文的文献

1
6
Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence.
Heart Fail Rev. 2023 May;28(3):585-596. doi: 10.1007/s10741-022-10238-6. Epub 2022 May 6.
7
Atractylenolide-I covalently binds to CYP11B2, selectively inhibits aldosterone synthesis, and improves hyperaldosteronism.
Acta Pharm Sin B. 2022 Jan;12(1):135-148. doi: 10.1016/j.apsb.2021.09.013. Epub 2021 Sep 21.
8
Antidiabetic effect of an engineered bacterium -pMG36e -GLP-1 in monkey model.
Synth Syst Biotechnol. 2021 Sep 17;6(4):272-282. doi: 10.1016/j.synbio.2021.09.009. eCollection 2021 Dec.
9
Using Latent Class Analysis to Identify Different Risk Patterns for Patients With Masked Hypertension.
Front Cardiovasc Med. 2021 Aug 25;8:680083. doi: 10.3389/fcvm.2021.680083. eCollection 2021.
10

本文引用的文献

3
Cardiac remodeling in patients with primary aldosteronism.
J Endocrinol Invest. 2009 Oct;32(9):739-45. doi: 10.1007/BF03346529.
4
Aldosterone-receptor antagonism in hypertension.
J Hypertens. 2009 Apr;27(4):680-91. doi: 10.1097/HJH.0b013e32832810ed.
5
Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension.
Ann Intern Med. 2009 Jun 2;150(11):776-83. doi: 10.7326/0003-4819-150-11-200906020-00005.
6
Metabolic syndrome in primary aldosteronism and essential hypertension: relationship to adiponectin gene variants.
Nutr Metab Cardiovasc Dis. 2010 Feb;20(2):93-100. doi: 10.1016/j.numecd.2009.03.007. Epub 2009 May 29.
7
Blood aldosterone-to-renin ratio, ambulatory blood pressure, and left ventricular mass in children.
J Pediatr. 2009 Aug;155(2):170-5. doi: 10.1016/j.jpeds.2009.02.029. Epub 2009 May 21.
9
Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat.
Am J Physiol Renal Physiol. 2009 May;296(5):F1013-22. doi: 10.1152/ajprenal.90646.2008. Epub 2009 Mar 4.
10
Aldosterone and metabolic dysfunction: an unresolved issue.
Hypertension. 2009 Apr;53(4):585-6. doi: 10.1161/HYPERTENSIONAHA.108.123406. Epub 2009 Feb 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验